MedPath

Opioid Package Prototype (OPP)

Not Applicable
Recruiting
Conditions
Opioid Use
Opioid Prescribing, Dispensing, and Patient Use
Interventions
Other: Opioid Package Prototype (OPP)
Other: Usual Care (standard amber vial)
Registration Number
NCT04598074
Lead Sponsor
UConn Health
Brief Summary

The overall objective of this clinical trial is to identify the impact of selected package features, known as the Opioid Package Prototype (OPP), on the safe and effective use of opioids. Our specific aims are: (Aim 1) to evaluate the effectiveness of OPP on prescribing, dispensing, and patient use of oxycodone among orthopaedic surgery patients receiving post-operative outpatient oxycodone for post-surgical pain management, and (Aim 2) to determine the feasibility of OPP for orthopaedic surgery prescribers, pharmacists, and orthopaedic surgery patients. Such data can be used to further optimize packaging and labeling design, help patients and caregivers utilize their medication and packaging correctly, and improve prescribing and dispensing habits. The central hypothesis is that the OPP will be more effective than the amber vial in efforts to reduce oxycodone prescribing among patients over 18 receiving short-term management of post orthopedic surgery pain.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
352
Inclusion Criteria
  1. The patient is 18 years and older;
  2. The patient is one of the participating surgeons;
  3. The patient is receiving orthopaedic surgery that involves the use of opioid medication for post-operative pain;
  4. The patient is willing to receive oxycodone medication;
  5. The patient is willing and able to receive medication at the UConn Health Specialty Pharmacy, located in the Exchange across the street from the main entrance of UConn Health;
  6. The patient is willing and able to use a MyChart account;
  7. The patient is able to read and understand English; and
  8. The patient is able to understand the study procedures and their involvement in the study.
Exclusion Criteria

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Opioid Package Prototype (OPP)Opioid Package Prototype (OPP)Oxycodone 5mg tablets dispensed in the Opioid Package Prototype (OPP) with frequency and quantities varying, depending on the type of surgical procedure performed, surgeon, and individual patient
Usual Care (standard amber vial)Usual Care (standard amber vial)Oxycodone 5mg tablets dispensed in the standard amber vial (usual care) with frequency and quantities varying, depending on the type of surgical procedure performed, surgeon, and individual patient
Primary Outcome Measures
NameTimeMethod
Average morphine milligram equivalent (MME) of oxycodone tablets prescribed/per participant3 months after surgery

Mean

Number of oxycodone tablets used by study participants3 months after surgery

Count via survey/interview/visual inspection/photograph

Number of tablets of oxycodone prescribed3 months after surgery

Count via medical/pharmacy records

Average morphine milligram equivalent (MME) of oxycodone tablets used/per participant3 months after surgery

Mean

Secondary Outcome Measures
NameTimeMethod
Amount of dispensing time per oxycodone prescription for each study participantTime of surgery and any refills up to 1 month after surgery

Log of dispensing start time (received prescription) and dispensing stop time (prescription ready for pick up)

Amount of counseling time per oxycodone prescription for each study participantTime of surgery and any refills up to 1 month after surgery

Log of counseling start time (start to discuss medication information) and counseling stop time (complete discussion of medication information)

Awareness of oxycodone medication information1 week and 1 month after surgery

Various survey/interview questions

Awareness of oxycodone tablets used1 week and 1 month after surgery

Amount of time to report number of tablets used via brief inspection of container (not manual count) during interview and various survey questions

SANE (Single Assessment Numeric Evaluation) scoreBaseline, 1 week, 1 month and 3 months after surgery

"How would you rate your affected joint/region of interest today as a percentage of normal (0% to 100% scale with 100% being normal)?"

PEG (Pain, Enjoyment of Life and General Activity) scoreBaseline, 1 week, 1 month and 3 months after surgery

A three-item scale assessing pain intensity and interference from 0-10. The three item scores are averaged for a final score and a higher number indicates greater pain and interference.

Feasibility of OPP for orthopaedic surgery prescribersWithin 1 month after prescribing the OPP to 30 participants

Interview regarding benefits and weaknesses of the OPP design, interest in prescribing OPP in the future, and how OPP design can be improved for the future

Feasibility of OPP for pharmacistsAfter dispensing all OPPs (approximately 2 years)

Interview questions regarding benefits and weaknesses of the OPP design, interest in dispensing OPP in the future, and how OPP design can be improved for the future

Peri-Operative Opioid-Related Symptom Distress Scale (OR-SDS)1 week, 1 month and 3 months after surgery

A 4-point scale that evaluates 3 symptom distress dimensions (frequency, severity, bothersomeness) for 12 symptoms. The symptom-specific ORSDS is the average of the 3 symptom distress dimensions. The composite ORSDS is the average of 12 symptom-specific scores.

Number of requests for additional oxycodone prescriptions1 week, 1 month and 3 months after surgery

Count per patient survey/interview

Change in knowledge of oxycodone from baseline to 1 weekBaseline (before surgery) and 1 week after surgery

Number of correct answers out of 4 knowledge questions

Consistency of access to oxycodone medication information1 week and 1 month after surgery

Various survey/interview questions

Pain Catastrophizing Scale (PCS)Baseline, 1 week, 1 month and 3 months after surgery

A 13-item scale, with a total range of 0 to 52. Higher scores are associated with higher amounts of pain catastrophizing.

Pain Medication Attitudes Questionnaire (PMAQ-14) scoreBaseline, 1 week, 1 month and 3 months after surgery

Participants indicate the degree to which they agree with 14 statements regarding pain medication from 0 (never true) to 5 (always true). The 14 scores are averaged for a final score and a higher number indicates a more negative attitude toward pain medications,

Patient Health Questionnaire-4 (PHQ-4)Baseline, 1 week and 1 month after surgery

A 4-item inventory rated on a 4-point Likert-type scale to assess for anxiety and depression. The minimum score (0) indicates no psychological distress and the maximum score (12) indicates severe psychological distress.

Feasibility of OPP for orthopaedic surgery patientsBetween 1 and 3 months after surgery

Interview questions regarding benefits and weaknesses of the OPP design, interest in using OPP in the future, and how OPP design can be improved for the future

Trial Locations

Locations (1)

UConn Health

🇺🇸

Farmington, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath